Possible tissue-specific effects were noted after treatment of breast cancer cells and CRC cells with cisplatin, oxaliplatin, and 5-FU, including enhanced downregulation IFN-β and TRAIL and upregulation of TRAIL-R2 in the breast cancer cells [238]. Here, TNFRSF10B is linked to breast cancer.